Barriers to counseling patients with obesity: A study of Texas community pharmacists

Journal of the American Pharmacists Association

Volumn 46, Issue 4, 2006, Pages 465-471

  O'Donnell, Dannielle C ^a,b,d   Brown, Carolyn M ^b   Dastani, Homa B ^c  

^a Medical Affairs   (United Kingdom)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d NONE   (United States)

Author keywords

Community and ambulatory pharmacy; Obesity; Patient counseling; Surveys

Indexed keywords

COMMUNITY CARE; HEALTH SURVEY; HUMAN; OBESITY; PATIENT COUNSELING; PHARMACIST; QUESTIONNAIRE; REIMBURSEMENT; REVIEW; UNITED STATES; WEIGHT REDUCTION; ARTICLE; COUNSELING; CROSS-SECTIONAL STUDY; FEMALE; MALE; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PHARMACY; PROFESSIONAL STANDARD;

COMMUNITY PHARMACY SERVICES; COUNSELING; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PHARMACISTS; PROFESSIONAL ROLE; TEXAS;

EID: 33748567135     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/154434506778073565     Document Type: Article

References (28)

1. Flegal KM, Carrol MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-7.
2. Small RE, Reeves R, Ferst K. Obesity: managing the comorbidities of the disease. J Am Pharm Assoc. 2000;40(suppl 1):S42-S43.
3. Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res. 1998;6:97-106.
4. U.S. Department of Health and Human Services. Healthy people 2010: understanding and improving health. 2nd ed. 2 vols. Washington, D.C.: U.S. Government Printing Office; 2000.
5. Lyznicki JM, Young DC, Riggs JA, Davis RM. Obesity: assessment and management in primary care. Am Fam Physician. 2001;63:2185-96.
6. Chandra A, Malcolm N, Fetters M. Practicing health promotion through pharmacy counseling activities. Health Promot Pract. 2003;4:64-71.
7. Babb VJ, Babb J. Pharmacist involvement in Healthy People 2010. J Am Pharm Assoc. 2003;43:56-60.
8. Campbell RK. Unraveling the mysteries of syndrome X. J Am Pharm Assoc. 2003;43(suppl 1):S32-S33.
9. Wadden TA, Berkowitz RI, Bogt RA, et al. Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach. Obes Res. 1997;5:218-26.
10. ASHP Commission on Therapeutics. ASHP therapeutic position statement on the safe use of pharmacotherapy for obesity management in adults. Am J Health Syst Pharm. 2001;58:1645-55.
11. Malone M, Alger-Mayer SA. Pharmacist intervention enhances adherence to orlistat therapy. Ann Pharmacother. 2003;37:1598-602.
12. Ahrens RA, Hower M, Best AM. Effects of weight reduction interventions by community pharmacists. J Am Pharm Assoc. 2003;43:583-9.
13. Dastani HB, Brown CM, O'Donnell DC. Combating the obesity epidemic: community pharmacists' counseling on obesity management. Ann Pharmacother. 2004;38:1961-3.
14. Raisch DW. Barriers to providing cognitive services. Am Pharm. 1993;NS33(12):54-8.
15. Herrier R, Boyce R. Why aren't more pharmacists counseling? Am Pharm. 1994;NS34(11):22-3.
16. Wiese HJC, Wilson JF, Jones RA, Neises M. Obesity stigma reduction in medical students. Int J Obes. 1992;16:859-68.
17. Price JH, Desmond SM, Krol RA, et al. Family practice physicians' beliefs, attitudes, and practices regarding obesity. Am J Prev Med. 1987;3:339-45.
18. Smith SR, Golin CE, Reif S. Influence of time stress and other variables on counseling by pharmacists about antiretroviral medications Am J Health Syst Pharm. 2004;61:1120-9.
19. O'Loughlin J, Masson P, Dery V, Fagnan D. The role of community pharmacists in health education and disease prevention: a survey of their interests and needs in relation to cardiovascular disease Prev Med. 1999;28:324-31.
20. Aquilino ML, Farris KB, Zillich AH, Lowe JB. Smoking-cessation services in Iowa community pharmacies. Pharmacotherapy. 2003;23:666-73.
21. Williams DM, Newsom JF, Brock TP. An evaluation of smoking cessation-related activities by pharmacists. J Am Pharm Assoc. 2000;40:366-70.
22. Ogden J, Bandara I, Cohen H, et al. General practitioners' and patients' models of obesity: whose problem is it? Patient Educ Couns. 2001;44:227-33.
23. Harvey EL, Hill AJ. Health professionals' views of overweight people and smokers. Int J Obes Relat Metab Disord. 2001;25:1253-61.
24. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532-46.
25. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med. 2004;164:994-1003.
26. Haddock CK, Poston WS, Dill PL, et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord. 2002;26:262-73.
27. Frank A. Futility and avoidance: medical professionals in the treatment of obesity. JAMA. 1993;269:2132-3.
28. Lyznicki JM, Young DC, Riggs JA, Davis RM. Obesity: assessment and management in primary care. Am Fam Physician. 2001;63:2185-96.